News

A deep dive into several noteworthy IgAN studies presented during the ERA 2025 Congress.

A RaDaR analysis from ERA 2025 provides insight into predictors of disease progression, outcomes in patients with Alport syndrome.

These phase 3b findings highlight lebrikizumab’s efficacy and safety in adult and adolescent patients with skin of color living with atopic dermatitis.

Most modern GDMT components were prescribed to less than half of all patients included in the EMPACE study, indicating the need for strategies to enhance clinical adoption.

This interview features a discussion with Lio regarding pediatric atopic dermatitis and the connection between caregivers, patients, and providers.

Michos discusses framing obesity as hyperandrogenism, with reductions in estrogen production contributing to higher visceral adiposity.

Discover groundbreaking insights on the VISIONARY trial, IgA nephropathy treatment, and the future of kidney care with expert Vlado Perkovic, MBBS, PhD.

Jonathan Barratt, MD, PhD, discusses results from an open-label trial of mezagitamab from ERA 2025.

Study findings highlight the potential utility of cardiac catheterization as a targeted intervention in pre-kidney transplant cardiac risk stratification.

Pagidipati describes barriers to implementing guideline-directed medical therapy in patients with cardiometabolic diseases and steps needed to overcome them.

Khan’s presentation indicates that combination screening is the optimal method of identifying heart failure risk while minimizing the percentage of cases missed.

A study presented at ERA 2025 validates the use of proteinuria as a surrogate endpoint for FSGS clinical trials.

The ACHIEVE trial found use of spironolcatone was not associated with a statistically significant reduction in cardiovascular death or hospitalization for HF.

This interview highlights 3 new topical non-steroidal options for atopic dermatitis covered in Kircik’s RAD 2025 presentation on FDA approvals.

An ERA 2025 analysis confirms empagliflozin significantly lowers acute kidney injury risk, reassuring clinicians about its safety in at-risk patients.

Hosts break down data from the CONFIDENCE trial on the safety and efficacy of finerenone plus empagliflozin in patients with T2D and CKD.

Discover the latest advancements in pulmonology, including innovative treatments for asthma, COPD, and pulmonary sarcoidosis, showcased at ATS 2025.

Semaglutide’s reduction in systolic blood pressure could indicate more potential for cardiovascular protection than simply its well-known glycemic benefits.

Alva and Meyer offer a glimpse into what attendees can expect in the schizophrenia portion of the Southern California Psychiatry Conference.

In this interview with Shahriari at RAD 2025, she highlights some of the most significant burdens that patients and caregivers face with atopic dermatitis.

Investigators compared the efficacy of tirzepatide and liraglutide in lowering rates of all-cause mortality in patients with obesity and sleep apnea.

In this Q&A interview, Silverberg highlighted takeaways from his talk at RAD 2025 on recent FDA approvals for atopic dermatitis.

52-week data from the VALIANT program shed further light on the potential of pegcetacoplan in C3G and IC-MPGN.

Prespecified analysis of 320 patients in VISIONARY were presented at ERA 2025 Congress.

In this session at RAD 2025, Tiffany Mayo, MD, spoke to attendees about several examples of complex cases in atopic dermatitis and touched on hair loss concerns.

New research has indicated that glucagon-like peptide-1 receptor agonists result in lower all-cause mortality and risk of cardiovascular events in patients with concurrent sleep apnea and type 2 diabetes.

In this video segment, Kircik described the data highlighted in his JAK inhibitor-related presentation at RAD 2025.